Enveric files $2,425,000 at-the-market offering supplement with H.C. Wainwright

Enveric Biosciences, Inc. filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of its common stock under an at-the-market offering agreement with H.C. Wainwright & Co., LLC. The company said it had already sold an aggregate of $4,483,711.04 through the same sales agent under that agreement before the new filing. The Form 8-K reporting the supplement was filed the same day under Item 8.01, Other Events.

The terms

The new shares are issuable under an At The Market Offering Agreement between Enveric and H.C. Wainwright & Co., LLC, which the filing calls the Sales Agent. The agreement is dated April 9, 2025. The prospectus supplement adds $2,425,000 of shares of common stock, par value $0.01 per share, to the amount that can be sold under that agreement.

The filing does not give a price per share or a number of shares that may be sold. It also does not say how the company plans to use the proceeds from these sales.

Banks and advisors

The filing names one sales agent for this program, H.C. Wainwright & Co., LLC. The 8-K does not name an underwriter, book-running manager or placement agent for this offering.

Greenberg Traurig, LLP gave the legal opinion on the legality of the shares issuable under the agreement, filed as Exhibit 5.1, and consented to its use in Exhibit 23.1, which is contained in Exhibit 5.1. The 8-K lists no other advisor by name.

The company

The company's annual report on Form 10-K, filed March 27, 2026, describes Enveric as a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. The report says its lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors. EB-003 is a novel derivative of N,N-Dimethyltryptamine, known as DMT.

According to the report, EB-003 is advancing through preclinical studies with the aim of starting first-in-human studies to assess safety and tolerability, including non-hallucinogenic properties. The company was incorporated in Delaware in February 1994 as Spatializer Audio Laboratories, Inc. Its principal corporate office is at 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142.

Recent financial data

The XBRL data that accompanies the company's filings states the following figures from the annual report filed March 27, 2026. For the fiscal year ended December 31, 2025, research and development expense was $2.8 million, net income (loss) was negative $8.8 million, and cash from operations was negative $8.1 million. For the fiscal year ended December 31, 2024, research and development expense was $2.8 million, net income (loss) was negative $9.6 million, and cash from operations was negative $7.7 million.

The annual report's business section describes the Psybrary library as including 20 patent families with claims covering a million potential molecular structures. It also says the company unveiled its EVM401 Series on February 25, 2025.

The risks ahead

Enveric has to keep paying for its preclinical work by selling stock. Sales under this program add shares to the count, and the 8-K gives no price per share, no share number and no plan for the proceeds. The XBRL data shows a net loss of $8.8 million and cash from operations of negative $8.1 million for 2025, set against the $2,425,000 added here. The annual report says EB-003 has completed short-term dose-range finding toxicology studies and still has to move into IND-enabling, GLP compliant safety pharmacology, ADMET and longer-term toxicology studies before first-in-human work. The 8-K sets no timetable for further sales.

Report an error

Companies in this story

ENVBEnveric Biosciences, Inc.NASDAQ · United StatesOpen the starter desk